UPDATE: Pain Therapeutics (PTIE), DURECT (DRRX) Sink in Active Trade
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts PTIE Hot Sheet
Join SI Premium – FREE
(Updated - November 1, 2012 11:13 AM EDT)
Both Pain Therapeutics Inc. (Nasdaq: PTIE) and DURECT Corporation (Nasdaq: DRRX) are under heavy pressure Thursday, raising eyebrows among traders. Pfizer had its conference call today and traders would have been looking for commentary on Remoxy. It is unclear at this point what, if anything Pfizer said.
PTIE is down 23 percent and DRRX is down 38 percent, having been halted numerous times.
UPDATE: It is now being said among biotech watchers that Pfizer noted "problems" lingering with FDA on the re-file.
From @adamfeuerstein on twitter:
RT @JNapodano: @adamfeuerstein Yes, apparently $PFE noted "problems" lingering with FDA on the re-file.
Both Pain Therapeutics Inc. (Nasdaq: PTIE) and DURECT Corporation (Nasdaq: DRRX) are under heavy pressure Thursday, raising eyebrows among traders. Pfizer had its conference call today and traders would have been looking for commentary on Remoxy. It is unclear at this point what, if anything Pfizer said.
PTIE is down 23 percent and DRRX is down 38 percent, having been halted numerous times.
UPDATE: It is now being said among biotech watchers that Pfizer noted "problems" lingering with FDA on the re-file.
From @adamfeuerstein on twitter:
RT @JNapodano: @adamfeuerstein Yes, apparently $PFE noted "problems" lingering with FDA on the re-file.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Baxter (BAX) sees early weakness
- US Treasury: 'Authorizing Wind Down Activities...the Offloading of Cargo Involving Certain Persons or Vessels Blocked on October 21, 2026'
- Novartis wins EU approval for Cosentyx in rheumatic disease
Create E-mail Alert Related Categories
FDA, Trader TalkRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
